Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Invested Capital (2016 - 2025)

Neurocrine Biosciences' Invested Capital history spans 16 years, with the latest figure at $3.3 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 25.62% year-over-year to $3.3 billion; the TTM value through Dec 2025 reached $3.3 billion, up 25.62%, while the annual FY2025 figure was $3.3 billion, 25.62% up from the prior year.
  • Invested Capital reached $3.3 billion in Q4 2025 per NBIX's latest filing, up from $3.0 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $3.3 billion in Q4 2025 to a low of $1.2 billion in Q1 2021.
  • Average Invested Capital over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: dropped 1.0% in 2021, then surged 48.94% in 2024.
  • A 5-year view of Invested Capital shows it stood at $1.4 billion in 2021, then soared by 36.62% to $1.9 billion in 2022, then rose by 27.96% to $2.4 billion in 2023, then rose by 7.81% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Invested Capital are $3.3 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.7 billion (Q2 2025).